Bersavine: A Novel Bisbenzylisoquinoline Alkaloidwith Cytotoxic, Antiproliferative and Apoptosis-Inducing Effects on Human Leukemic Cells.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
20 Feb 2020
Historique:
received: 20 01 2020
revised: 18 02 2020
accepted: 19 02 2020
entrez: 26 2 2020
pubmed: 26 2 2020
medline: 20 11 2020
Statut: epublish

Résumé

Bersavine is the new bisbenzylisoquinoline alkaloid isolated from the Berberis vulgaris L.(Berberidaceae) plant. The results of cytotoxicity screening 48 h post-treatment showed thatbersavine considerably inhibits the proliferation and viability of leukemic (Jurkat, MOLT-4), colon(HT-29), cervix (HeLa) and breast (MCF-7) cancer cells with IC50 values ranging from 8.1 to 11 μM.The viability and proliferation of leukemic Jurkat and MOLT-4 cells were decreased after bersavinetreatment in a time- and dose-dependent manner. Bersavine manifested concentration-dependentantiproliferative activity in human lung, breast, ovarian and hepatocellular carcinoma cell linesusing a xCELLigence assay. Significantly higher percentages of MOLT-4 cells exposed to bersavineat 20 μM for 24 h were arrested in the G1 phase of the cell cycle using the flow cytometry method.The higher percentage of apoptotic cells was measured after 24 h of bersavine treatment. Theupregulation of p53 phosphorylated on Ser392 was detected during the progression of MOLT-4 cellapoptosis. Mechanistically, bersavine-induced apoptosis is an effect of increased activity ofcaspases, while reduced proliferation seems dependent on increased Chk1 Ser345 phosphorylationand decreased Rb Ser807/811 phosphorylation in human leukemic cells.

Identifiants

pubmed: 32093423
pii: molecules25040964
doi: 10.3390/molecules25040964
pmc: PMC7071104
pii:
doi:

Substances chimiques

Alkaloids 0
Antineoplastic Agents, Phytogenic 0
Cytotoxins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : European Union
ID : CZ.02.1.01/0.0/0.0/18_069/0010046
Organisme : Charles University
ID : Progres/UK Q40/01
Organisme : Charles University
ID : SVV-260397/2017

Références

J Zhejiang Univ Sci B. 2011 Jul;12(7):568-74
pubmed: 21726064
Cytotechnology. 2018 Feb;70(1):321-329
pubmed: 28965196
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2009 Sep;38(5):439-44
pubmed: 19830854
Curr Med Chem. 2018;25(38):5088-5114
pubmed: 28933285
Sci Rep. 2017 Jul 19;7(1):5806
pubmed: 28724926
J Med Chem. 2008 May 8;51(9):2589-99
pubmed: 18393402
Lancet Oncol. 2018 Mar;19(3):293-294
pubmed: 29508748
Prostate Cancer Prostatic Dis. 2016 Dec;19(4):358-366
pubmed: 27431500
J Nat Prod. 2019 Feb 22;82(2):239-248
pubmed: 30701972
Acta Pharmacol Sin. 2009 Dec;30(12):1659-65
pubmed: 19960011
Alkaloids Chem Biol. 2019;82:147-304
pubmed: 30850031
Asian Pac J Cancer Prev. 2014;15(4):1767-9
pubmed: 24641406
Evid Based Complement Alternat Med. 2017;2017:8152526
pubmed: 28883885
J Zhejiang Univ Sci B. 2007 Apr;8(4):248-55
pubmed: 17444599
J Asian Nat Prod Res. 2009;11(3):219-28
pubmed: 19408145
Oncol Res. 2013;20(7):265-74
pubmed: 23879166
Anat Rec (Hoboken). 2014 May;297(5):802-9
pubmed: 24619961

Auteurs

Darja Koutova (D)

Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic.

Monika Kulhava (M)

Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic.

Radim Havelek (R)

Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic.

Martina Majorosova (M)

Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic.

Karel Královec (K)

Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University ofPardubice, Studentska 573, 532 10 Pardubice, Czech Republic.

Klara Habartova (K)

Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic.

Anna Hošťálková (A)

ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.

Lubomír Opletal (L)

ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.

Lucie Cahlikova (L)

ADINACO Research Group, Department of Pharmaceutical Botany, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.

Martina Řezáčová (M)

Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03 Hradec Kralove, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH